Search - Université de Rennes Access content directly

Filter your results

29 Results
authFullName_s : G. Bouguen

Patients' point of view regarding acceptability and usefulness of inflammatory bowel diseases monitoring tools: results from a nationwide multicentre study (the ACCEPT study)

A. Buisson , F. Gonzalez , F. Poullenot , S. Nancey , E. Sollellis et al.
Journal of Crohn's and Colitis, 2016, 10 (suppl 1), pp.S149--S149. ⟨10.1093/ecco-jcc/jjw019.240⟩
Journal articles hal-01481458v1

Adults with Spina Bifida have alterations of rectal and intestinal epithelial barrier functions

C. Brochard , R. Olivier , A. Ropert , E. Coron , L. Siproudhis et al.
Neurogastroenterology & Motility, 2018, 30
Journal articles hal-01879624v1

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

L. Peyrin-Biroulet , W. Sandborn , B. E. Sands , W. Reinisch , W. Bemelman et al.
The American Journal of Gastroenterology, 2015, 110 (9), pp.1324-38. ⟨10.1038/ajg.2015.233⟩
Journal articles hal-01191653v1
Image document

Anoperineal lesions in Crohn’s disease: French recommendations for clinical practice

D. Bouchard , L. Abramowitz , G. Bouguen , C. Brochard , A. Dabadie et al.
Techniques in Coloproctology, 2017, 21 (9), pp.683-691. ⟨10.1007/s10151-017-1684-y⟩
Journal articles hal-01639851v1

Autoimmune pancreatitis associated with inflammatory bowel disease: a multicentric study of the GETAID

D. Lorenzo , F. Maire , C. Stefanescu , J. M. Gornet , P. Seksik et al.
Journal of Crohn's and Colitis, 2016, 10 (4), pp.S221--S222. ⟨10.1016/S0016-5085(16)30830-7⟩
Journal articles hal-01335059v1

Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience

J. Filippi , D. Laharie , C. Michiels , M. Flamand , G. Bouguen et al.
Journal of Crohn's & Colitis, 2015, 9 (3), pp.252--258. ⟨10.1093/ecco-jcc/jjv001⟩
Journal articles hal-01146924v1

Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis

A. Dignass , A. Akbar , D.C. Baumgart , G. Bommelaer , G. Bouguen et al.
Scandinavian Journal of Gastroenterology, 2018, 53 (4), pp.442-448. ⟨10.1080/00365521.2018.1447598⟩
Journal articles hal-01880990v1

Prospective cohort study of phenotypic variation based on an anal sphincter function in adults with fecal incontinence

C. Brochard , G. Bouguen , A. Bodère , A. Ropert , A.-L. Mallet et al.
Neurogastroenterology & Motility, 2016, 28 (10), pp.1554--1560. ⟨10.1111/nmo.12855⟩
Journal articles hal-01380420v1

One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

A. Amiot , M. Serrero , L. Peyrin-Biroulet , J. Filippi , B. Pariente et al.
Alimentary Pharmacology & Therapeutics (Suppl), 2017, 46 (3), pp.310-321. ⟨10.1111/apt.14167⟩
Journal articles hal-01639670v1

Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

A. Buisson , M. Nachury , Mathurin Fumery , T. Guilmoteau , E. Leclerc et al.
Journal of Crohn's and Colitis, 2022, 16 (1), pp.I120
Journal articles hal-03665871v1

A negative screening does not eliminate tuberculosis risk under anti-TNF treatment in inflammatory bowel disease: a descriptive study

Y. Abitbol , D. Laharie , J. Cosnes , M. Allez , S. Nancey et al.
Journal of Crohn's and Colitis, 2016, 10 (4), pp.S382--S382. ⟨10.1016/S0016-5085(16)31437-8⟩
Journal articles hal-01335062v1

Recommandations de pratique pour le diagnostic et la prise en charge de la rectocolite hémorragique

A. Amiot , S. Viennot , M. Uzzan , P. Riviere , G.L. Cosquer et al.
Hépato-Gastro & Oncologie Digestive, 2022, 29 (3), pp.1-55. ⟨10.1684/hpg.2022.2336⟩
Journal articles hal-03718114v1

Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?

B. Franck , M.C. Verdier , E. Bellissant , G. Bouguen , F. Lemaitre et al.
Fundamental & Clinical Pharmacology, 2022, 36, pp.43-43
Journal articles hal-03789365v1

Comment extrapoler le concept de treat-to-target à la rectocolite hémorragique?

G. Bouguen
Hépato-Gastro & Oncologie Digestive, 2018, 25, pp.34-40. ⟨10.1684/hpg.2018.1671⟩
Journal articles hal-02042388v1

Anal ulcerations in Crohn's disease: Natural history in the era of biological therapy

T. Wallenhorst , C. Brochard , E. Le Balch , A. Bodere , A. Garros et al.
Digestive and Liver Disease, 2017, 49 (11), pp.1191-1195. ⟨10.1016/j.dld.2017.07.014⟩
Journal articles hal-01637192v1

Pathophysiology of fecal incontinence in obese patients: A prospective case-matched study of 201 patients

C. Brochard , A. Venara , A. Bodère , A. Ropert , G. Bouguen et al.
Neurogastroenterology & Motility, 2017, 29 (8), pp.e13051. ⟨10.1111/nmo.13051⟩
Journal articles hal-01577963v1

Prise en charge des maladies inflammatoires chroniques intestinales: Mise à jour 2021

A. Amiot , G. Bouguen , G. Bonnaud , Y. Bouhnik , H. Hagège et al.
Hépato-Gastro & Oncologie Digestive, 2021, 28 (4), pp.441-477. ⟨10.1684/hpg.2021.2160⟩
Journal articles hal-03420462v1

Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

C. Cottron , X. Treton , R. Altwegg , C. Reenaers , A. Amiot et al.
Journal of Crohn's and Colitis, 2022, 16 (Supplement_1), pp.I502-I502. ⟨10.1093/ecco-jcc/jjab232.684⟩
Journal articles hal-03687586v1

Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study

Dana Duricova , H. Sarter , G. Savoye , A. Leroyer , B. Pariente et al.
Journal of Crohn's & Colitis, 2018, 12 (supp1), pp.S531-S532. ⟨10.1093/ecco-jcc/jjx180.949⟩
Journal articles hal-03552414v1
Image document

Letter: wide variation in faecal calprotectin values according to the assay

S. Sun , T. Cavey , L. Peltier , C. Bendavid , G. Bouguen et al.
Alimentary Pharmacology and Therapeutics, 2016, 43 (1), pp.166-180. ⟨10.1111/apt.13455⟩
Journal articles hal-01243033v1

Natural history of perianal Crohn's disease: long-term follow-up on a population-based cohort

M. -L. Rabilloud , A. -L. Mallet , L. Siproudhis , Emma Bajeux , Jean François Viel et al.
Journal of Crohn's and Colitis, 2016, 10 (suppl 1), pp.S175--S176. ⟨10.1093/ecco-jcc/jjw019.290⟩
Journal articles hal-01359565v1

Bowel Dysfunction Related to Spina Bifida: Keep It Simple

C. Brochard , B. Peyronnet , A. Dariel , H. Ménard , A. Manunta et al.
Diseases of the Colon & Rectum, 2017, 60 (11), pp.1209-1214. ⟨10.1097/DCR.0000000000000892⟩
Journal articles hal-01637194v1

Effects of transcutaneous tibial nerve stimulation on anorectal physiology in fecal incontinence: a double-blind placebo-controlled cross-over evaluation.

G. Bouguen , A. Ropert , F. Lainé , P. Pequin , J. Morcet et al.
Neurogastroenterology & Motility, 2014, 26 (2), pp.247-54. ⟨10.1111/nmo.12256⟩
Journal articles hal-00949405v1

Anorectal dysfunction in patients with ulcerative colitis: impaired adaptation or enhanced perception?

C. Brochard , L. Siproudhis , A. Ropert , A. Mallak , J.-F. Bretagne et al.
Neurogastroenterology & Motility, 2015, 27 (7), pp.1032-1037. ⟨10.1111/nmo.12580⟩
Journal articles hal-01151618v1

Efficacy of anti-TNF treatment in patients with refractory ulcerative proctitis: Results from a French retrospective multi-centre national cohort

G. Pineton De Chambrun , A. Amiot , G. Bouguen , S. Viennot , R. Altwegg et al.
Journal of Crohn's and Colitis, 2018, 12 (1), pp.S479-S480
Journal articles hal-03552413v1

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Mathurin Fumery , J. Filippi , V. Abitbol , A. Biron , D. Laharie et al.
Journal of Crohn's and Colitis, 2021, 15 (1), pp.S486-S487. ⟨10.1093/ecco-jcc/jjab076.626⟩
Journal articles hal-03552093v1
Image document

Long-term outcomes and predictors of disabling disease in a population-based cohort of patients with incident Crohn's disease diagnosed between 1994 and 1997

M.-L. Rabilloud , E. Bajeux , L Siproudhis , S. Hamonic , M. Pagenault et al.
Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (9), pp.101974. ⟨10.1016/j.clinre.2022.101974⟩
Journal articles hal-03780614v1

Reply: Response to: Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection

A. Petitcollin , G. Bouguen
Clinical Gastroenterology and Hepatology, 2021, 19 (11), pp.2458-2459. ⟨10.1016/j.cgh.2020.07.001⟩
Journal articles hal-03268992v1

Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Benoît Caron , L. Peyrin-Biroulet , M. Nachury , Y. Bouhnik , P. Seksik et al.
Journal of Crohn's and Colitis, 2018, 12 (1), pp.S278
Journal articles hal-03552412v1